Willingness to Participate in a Daily Smartphone Well-being Study

March 6, 2025 updated by: Abdur-Rahman, University of Manchester

Comparing the Effectiveness of Non-financial Incentive to Participate in a Smartphone Experience Sampling Method Well-being Study: Protocol for a Randomised Controlled Trial

This clinical trial aims to compare the effectiveness of financial and social incentives in motivating urban populations to participate in Experience Sampling Method (ESM) wellbeing studies and explore alternative incentive preferences to increase participation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The goal of this clinical trial is to investigate the comparison of two incentives to determine their effectiveness for motivating an urban population to participate in a Experience Sampling Method wellbeing studies. It will also investigate alternative incentive preferences that can motivate the population. The main questions it aims to answer are:

  • Does the provision of a financial incentive or social incentive to neighbourhood research participants increase the willingness of individuals to participate in ESM research compared to offering no incentive?
  • What are the reasons for unwillingness to participate in ESM studies?
  • What are the alternative incentive preference that could increase willingness to participate in ESM studies?

Researchers will compare monetary incentive (4 x £100 prize draw qualification) to a non-monetary incentive (invitation to end of project social event to engage research findings) to how they influence willingness to participate compared to offering no incentive.

Participants will:

  • Receive receive an email describing a future experience sampling study in the neighbourhood for at least two times.
  • Complete a survey to indicate their positive or negative interest in the hypothetical study.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
324

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Greater London
      • London, Greater London, United Kingdom, N1C 4AB
        • Related Argent

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Registered on the King's Cross community smartphone application.
  • App users living, working, or have previously visited King's Cross
  • Given consent to receive email communications during their smartphone app sign-up.

Exclusion Criteria:

  • Users of the King's Cross community smartphone app who have not given consent to receive email communication about the neighbourhood

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Control Group
Participants in this group will receive no incentive for participating in the future experience sampling study.
Behavioral: No Incentive Email
Participant will receive an email describing a hypothetical experience sampling study that will happen in King's Cross where he or she is an inhabitant as a worker, resident, or visitor. However, this email will not include any promised compensation for future participation in the hypothetical wellbeing study in the neighbourhood. This group serves as the control group to compare the effects of incentives on participation rates.
Experimental: Financial Incentive Group
Participants in this group will receive a financial incentive for participating in the future experience sampling study.
Behavioral: Financial Incentive Email
Participant will receive an email describing a hypothetical experience sampling study that will happen in King's Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a financial compensation, which is a chance of enter a prize draw to win a 4 X £100 voucher which can be used to purchase goods and services within the King's Cross neighbourhood in London.
Experimental: Non-Financial Incentive Group
Participants in this group will receive a non-financial incentive for participating in the future experience sampling study.
Behavioral: Social Incentive Email
Participant will receive an email describing a hypothetical experience sampling study that will happen in King's Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a non-financial compensation, which is an invitation to participate in a social event that will be organised by the researchers and the neighbourhood asset manager team at the end of the research project. This event will be exclusive and it will be an opportunity for participants to socialize with other study participants in the neighbourhood. It will also be an opportunity for the study participants to feel they are contributing a change to the neighbourhood and will be able to articulate their views about the wellbeing research findings which is expected to be used to inform future interventions in the neighbourhood.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Willingness to participate
Time Frame: From enrollment to the end of treatment at 7 weeks
Measure the proportion of participants in each arm who agree to participate in the experience sampling study.
From enrollment to the end of treatment at 7 weeks

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Reasons for non-participation
Time Frame: From enrollment to the end of treatment at 7 weeks
Participants who are not willing to participate in the future experience sampling study will be asked to indicate four out of seven reasons for the unwillingness.
From enrollment to the end of treatment at 7 weeks
Alternative Incentive Preferences
Time Frame: From enrollment to the end of treatment at 7 weeks
Participants who are not willing to participate in the future experience sampling study and who select "inadequate compensation" as one of the reasons for not participating will be asked to select desired incentives from a list of seven options that could motivate a change in participation decision.
From enrollment to the end of treatment at 7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Manchester

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Economic and Social Research Council, United Kingdom

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Lesley-Anne Carter, University of Manchester
  • Principal Investigator: Jack Benton, University of Manchester
  • Principal Investigator: Jamie Anderson, University of Manchester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 12, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 30, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 5, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 5, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 6, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023-17042-30162

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

With the exception of the identifying email addresses, the demographic and outcome data that was collected from the participant will be publicly made available on UK Data Service ReShare, a platform for archiving research data.

IPD Sharing Time Frame

Data requests can be submitted starting 12 months after article publication and the duration the data will be made accessible for is based on the terms and conditions attached to the ReShare platform where the data will be archived.

IPD Sharing Access Criteria

Access to trial IPD can be requested by qualified researchers engaging in independent scientific research

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings